FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380873904> ?p ?o ?g. }

• W4380873904 abstract "Abstract Introduction Population-level data on durable HIV viral load suppression (VLS) following implementation of Universal Test and Treat (UTT) in Africa are limited. We assessed trends in durable VLS and viremia among persons living with HIV in 40 Ugandan communities during UTT scale-up. Methods In 2015-2020, we measured VLS (defined as <200 RNA copies/mL) among participants in the Rakai Community Cohort Study, a longitudinal population-based HIV surveillance cohort in southern Uganda. Persons with unsuppressed viral loads were characterized as having low-level (200-999 copies/mL) or high-level (≥1,000 copies/mL) viremia. Individual virologic outcomes were assessed over two consecutive RCCS survey visits (i.e., visit-pairs; ∼18 month visit intervals) and classified as durable VLS (<200 copies/mL at both visits), new/renewed VLS (<200 copies/mL at follow-up only), viral rebound (<200 copies/mL at initial visit only), or persistent viremia (<200 copies/mL at neither visit). Population prevalence of each outcome was assessed over calendar time. Community-level prevalence and individual-level predictors of persistent high-level viremia were also assessed using multivariable Poisson regression with generalized estimating equations. Results Overall, 3,080 participants contributed 4,604 visit-pairs over three survey rounds. Most visit-pairs (72.4%) exhibited durable VLS, with few (2.5%) experiencing viral rebound. Among those with viremia at the initial visit ( n =1,083), 46.9% maintained viremia through follow-up, 91.3% of which was high-level viremia. One-fifth (20.8%) of visit-pairs exhibiting persistent high-level viremia self-reported antiretroviral therapy (ART) use for ≥12 months. Prevalence of persistent high-level viremia varied substantially across communities and was significantly elevated among young persons aged 15-29 years (versus 40-49-year-olds; adjusted risk ratio [adjRR]=2.96; 95% confidence interval [95%CI]:2.21-3.96), men (versus women; adjRR=2.40, 95%CI:1.87-3.07), persons reporting inconsistent condom use with non-marital/casual partners (versus persons with marital/permanent partners only; adjRR=1.38, 95%CI:1.10-1.74), and persons exhibiting hazardous alcohol use (adjRR=1.09, 95%CI:1.03-1.16). The prevalence of persistent high-level viremia was highest among men <30 years (32.0%). Conclusions Following universal ART provision, most persons living with HIV in south-central Uganda are durably suppressed. Among persons exhibiting viremia, nearly half maintain high-level viremia for ≥12 months and report higher-risk behaviors associated with onward HIV transmission. Enhanced linkage to HIV care and optimized treatment retention could accelerate momentum towards HIV epidemic control." @default.
• W4380873904 created "2023-06-17" @default.
• W4380873904 creator A5004877246 @default.
• W4380873904 creator A5010629071 @default.
• W4380873904 creator A5014426318 @default.
• W4380873904 creator A5016126068 @default.
• W4380873904 creator A5019872491 @default.
• W4380873904 creator A5020176794 @default.
• W4380873904 creator A5026518567 @default.
• W4380873904 creator A5030108883 @default.
• W4380873904 creator A5035796355 @default.
• W4380873904 creator A5053337081 @default.
• W4380873904 creator A5064298782 @default.
• W4380873904 creator A5066564090 @default.
• W4380873904 creator A5066813235 @default.
• W4380873904 creator A5068290358 @default.
• W4380873904 creator A5071403911 @default.
• W4380873904 creator A5073671389 @default.
• W4380873904 creator A5075573079 @default.
• W4380873904 creator A5077362439 @default.
• W4380873904 creator A5081157745 @default.
• W4380873904 creator A5083934959 @default.
• W4380873904 creator A5085065909 @default.
• W4380873904 creator A5085083138 @default.
• W4380873904 creator A5091806880 @default.
• W4380873904 date "2023-06-16" @default.
• W4380873904 modified "2023-09-27" @default.
• W4380873904 title "Temporal dynamics and drivers of durable HIV viral load suppression and persistent high- and low-level viremia during Universal Test and Treat scale-up in Uganda: a population-based study" @default.
• W4380873904 cites W1754691347 @default.
• W4380873904 cites W1895490982 @default.
• W4380873904 cites W2011236400 @default.
• W4380873904 cites W2030401719 @default.
• W4380873904 cites W2091541421 @default.
• W4380873904 cites W2102846799 @default.
• W4380873904 cites W2110776215 @default.
• W4380873904 cites W2119366692 @default.
• W4380873904 cites W2142495742 @default.
• W4380873904 cites W2461009619 @default.
• W4380873904 cites W2469408700 @default.
• W4380873904 cites W2469642414 @default.
• W4380873904 cites W2551018979 @default.
• W4380873904 cites W2610986922 @default.
• W4380873904 cites W2623667858 @default.
• W4380873904 cites W2747680863 @default.
• W4380873904 cites W2767089427 @default.
• W4380873904 cites W2770159128 @default.
• W4380873904 cites W2772512741 @default.
• W4380873904 cites W2775758586 @default.
• W4380873904 cites W2782776732 @default.
• W4380873904 cites W2923480101 @default.
• W4380873904 cites W2947395355 @default.
• W4380873904 cites W2958867317 @default.
• W4380873904 cites W2960675107 @default.
• W4380873904 cites W2961360820 @default.
• W4380873904 cites W2961470236 @default.
• W4380873904 cites W3005568012 @default.
• W4380873904 cites W3006735625 @default.
• W4380873904 cites W3007548335 @default.
• W4380873904 cites W3009801556 @default.
• W4380873904 cites W3015356306 @default.
• W4380873904 cites W3016239703 @default.
• W4380873904 cites W3016706534 @default.
• W4380873904 cites W3037312116 @default.
• W4380873904 cites W3109528548 @default.
• W4380873904 cites W3126055872 @default.
• W4380873904 cites W3173983975 @default.
• W4380873904 cites W3197806257 @default.
• W4380873904 cites W3198698979 @default.
• W4380873904 cites W3213735842 @default.
• W4380873904 cites W4205338174 @default.
• W4380873904 cites W4296704484 @default.
• W4380873904 cites W4309107154 @default.
• W4380873904 doi "https://doi.org/10.1101/2023.06.15.23291445" @default.
• W4380873904 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37398460" @default.
• W4380873904 hasPublicationYear "2023" @default.
• W4380873904 type Work @default.
• W4380873904 citedByCount "0" @default.
• W4380873904 crossrefType "posted-content" @default.
• W4380873904 hasAuthorship W4380873904A5004877246 @default.
• W4380873904 hasAuthorship W4380873904A5010629071 @default.
• W4380873904 hasAuthorship W4380873904A5014426318 @default.
• W4380873904 hasAuthorship W4380873904A5016126068 @default.
• W4380873904 hasAuthorship W4380873904A5019872491 @default.
• W4380873904 hasAuthorship W4380873904A5020176794 @default.
• W4380873904 hasAuthorship W4380873904A5026518567 @default.
• W4380873904 hasAuthorship W4380873904A5030108883 @default.
• W4380873904 hasAuthorship W4380873904A5035796355 @default.
• W4380873904 hasAuthorship W4380873904A5053337081 @default.
• W4380873904 hasAuthorship W4380873904A5064298782 @default.
• W4380873904 hasAuthorship W4380873904A5066564090 @default.
• W4380873904 hasAuthorship W4380873904A5066813235 @default.
• W4380873904 hasAuthorship W4380873904A5068290358 @default.
• W4380873904 hasAuthorship W4380873904A5071403911 @default.
• W4380873904 hasAuthorship W4380873904A5073671389 @default.
• W4380873904 hasAuthorship W4380873904A5075573079 @default.
• W4380873904 hasAuthorship W4380873904A5077362439 @default.
• W4380873904 hasAuthorship W4380873904A5081157745 @default.
• W4380873904 hasAuthorship W4380873904A5083934959 @default.
• W4380873904 hasAuthorship W4380873904A5085065909 @default.
• W4380873904 hasAuthorship W4380873904A5085083138 @default.

• next